CL2019002557A1 - Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. - Google Patents

Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.

Info

Publication number
CL2019002557A1
CL2019002557A1 CL2019002557A CL2019002557A CL2019002557A1 CL 2019002557 A1 CL2019002557 A1 CL 2019002557A1 CL 2019002557 A CL2019002557 A CL 2019002557A CL 2019002557 A CL2019002557 A CL 2019002557A CL 2019002557 A1 CL2019002557 A1 CL 2019002557A1
Authority
CL
Chile
Prior art keywords
wee
useful
pyrimidopyrimidinones
kinase inhibitors
compound
Prior art date
Application number
CL2019002557A
Other languages
English (en)
Inventor
Peter Hewitt
Frank Burkamp
Andrew Wilkinson
Hugues Miel
Colin O'dowd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CL2019002557A1 publication Critical patent/CL2019002557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO QUE ES ÚTIL COMO UN INHIBIDOR DE LA ACTIVIDAD DE LA QUINASA WEE-1. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTE COMPUESTO Y A MÉTODOS PARA USAR ESTE COMPUESTO EN EL TRATAMIENTO DEL CÁNCER Y MÉTODOS PARA TRATAR EL CÁNCER.
CL2019002557A 2017-03-10 2019-09-06 Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. CL2019002557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1703881.1A GB201703881D0 (en) 2017-03-10 2017-03-10 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CL2019002557A1 true CL2019002557A1 (es) 2019-12-27

Family

ID=58605309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002557A CL2019002557A1 (es) 2017-03-10 2019-09-06 Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.

Country Status (30)

Country Link
US (2) US11208413B2 (es)
EP (1) EP3592745B1 (es)
JP (1) JP7244430B2 (es)
KR (1) KR102605546B1 (es)
CN (1) CN110603256B (es)
AU (1) AU2018231671B2 (es)
BR (1) BR112019018753A2 (es)
CA (1) CA3055874A1 (es)
CL (1) CL2019002557A1 (es)
CY (1) CY1124613T1 (es)
DK (1) DK3592745T3 (es)
EA (1) EA201992137A1 (es)
ES (1) ES2895365T3 (es)
GB (1) GB201703881D0 (es)
HR (1) HRP20211652T1 (es)
HU (1) HUE056220T2 (es)
IL (1) IL269063B (es)
LT (1) LT3592745T (es)
MA (1) MA47736B1 (es)
MX (1) MX2019010554A (es)
MY (1) MY195580A (es)
PH (1) PH12019502049A1 (es)
PL (1) PL3592745T3 (es)
PT (1) PT3592745T (es)
RS (1) RS62464B1 (es)
SA (1) SA519410093B1 (es)
SG (1) SG11201908114UA (es)
SI (1) SI3592745T1 (es)
UA (1) UA125093C2 (es)
WO (1) WO2018162932A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
BR112021019703A2 (pt) 2019-04-09 2021-12-14 Nuvation Bio Inc Compostos heterocíclicos e usos dos mesmos
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
WO2023170065A1 (en) * 2022-03-07 2023-09-14 Debiopharm International S.A. Methods of treating small cell lung cancer
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2376494A4 (en) 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CN110603256A (zh) 2019-12-20
PH12019502049A1 (en) 2020-06-29
AU2018231671A1 (en) 2019-09-26
SA519410093B1 (ar) 2022-07-16
CA3055874A1 (en) 2018-09-13
US20220194947A1 (en) 2022-06-23
MY195580A (en) 2023-02-02
SI3592745T1 (sl) 2021-12-31
MA47736B1 (fr) 2021-10-29
WO2018162932A1 (en) 2018-09-13
GB201703881D0 (en) 2017-04-26
KR20190128673A (ko) 2019-11-18
CY1124613T1 (el) 2022-07-22
CN110603256B (zh) 2022-10-28
HRP20211652T1 (hr) 2022-02-04
JP7244430B2 (ja) 2023-03-22
LT3592745T (lt) 2021-11-10
PL3592745T3 (pl) 2022-01-03
IL269063A (en) 2019-11-28
UA125093C2 (uk) 2022-01-05
SG11201908114UA (en) 2019-10-30
US11208413B2 (en) 2021-12-28
DK3592745T3 (da) 2021-10-18
KR102605546B1 (ko) 2023-11-22
AU2018231671B2 (en) 2022-03-24
US20210128560A1 (en) 2021-05-06
IL269063B (en) 2022-04-01
PT3592745T (pt) 2021-10-20
RS62464B1 (sr) 2021-11-30
EP3592745B1 (en) 2021-07-28
BR112019018753A2 (pt) 2020-04-07
EP3592745A1 (en) 2020-01-15
JP2020510040A (ja) 2020-04-02
ES2895365T3 (es) 2022-02-21
MA47736A (fr) 2021-04-21
MX2019010554A (es) 2019-12-16
HUE056220T2 (hu) 2022-02-28
EA201992137A1 (ru) 2020-02-05

Similar Documents

Publication Publication Date Title
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
ECSP20069404A (es) Piridazinonas como inhibidoras de parp7
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP17070706A (es) Inhibidores de bromodominio
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
NI201600056A (es) Inhibidores de bromodominio
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2016000173A (es) Heteroarilos y usos de estos
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
SV2016005279A (es) Inhibidores de diacilglicerol aciltransferasa 2
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
ECSP14030779A (es) Inhibidores del nampt
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
BR112022001291A2 (pt) Amidas heterobicíclicas como inibidores de cd38
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.